Innovacell develops innovative cell therapies targeting the causes of fecal and urinary incontinence. Their regenerative treatments focus on permanent solutions using autologous muscle cells.

Innovacell is dedicated to developing advanced cell therapies for treating incontinence, aiming to regenerate damaged tissues. With a strong focus on scientific and clinical excellence, the company is advancing therapies such as ICES13 and ICEF15 for bladder and bowel control. Their proprietary technologies also include a cutting-edge cell isolation method and a precise injection system for targeted treatment.

Key Products and Services

• ICES13: Regenerative therapy for stress urinary incontinence
• ICEF15: Cell therapy for fecal incontinence (urge type)
• ICEF16: Treatment for fecal incontinence (passive type)
• Contract research and development services
• Contract manufacturing and analysis of Advanced Therapy Medicinal Products (ATMPs)

Innovacell continues to drive forward its mission to revolutionise incontinence care with innovative, safe, and minimally invasive solutions.